Published date:
19/01/2023
Summary:
– Vutrisiran is one of the first rare disease medicines to receive a positive draft recommendation under a streamlined pilot process from the National Institute for Health and Care Excellence (NICE) that aims to expedite patient access to promising new treatments[i]
MAIDENHEAD, UK, 19th January 2023 – Alnylam UK Limited, the leading RNA interference (RNAi) therapeutics company, today welcomed a draft decision from the National Institute for Health and Care Excellence (NICE) recommending the use of AMVUTTRA® (vutrisiran) on the NHS in England as an option for treating hereditary transthyretin-related (ATTRv) amyloidosis.[ii] Vutrisiran, a subcutaneous injection administered once every three months, seeks to address the root cause of ATTRv amyloidosis by reducing the production of the abnormal protein (amyloid)
